Late July 2026

the panel that voted on bpc-157 also voted on tb-500 — with an even emptier evidence file

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee worked through four peptides in a single session: BPC-157, KPV, TB-500, and MOTS-c. Each was evaluated for specific disease-state indications — not for the recovery and performance claims that drive their internet search volumes. TB-500's designated application was wound healing. [The full meeting record is on the FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026). Before the panel voted, FDA career scientists delivered their evidence review. On TB-500, the conclusion was stark: no direct human administration studies existed, and no human exposure data had been submitted to support the wound healing application. The panel voted yes anyway — recommending TB-500 for the 503A affirmative list. That vote now sits in a rulemaking queue that will take at least 8 to 12 months to resolve. The internet already moved on from the vote. The evidence problem it exposed has not resolved.

The actual molecule

tb-500 is sold as a thymosin beta-4 fragment — the connection is real, but the borrowing is extensive

Thymosin beta-4 is an endogenous peptide, present in virtually every cell in the body, with a well-characterized role in actin sequestration and cell motility. It does not circulate freely as a hormone — it works intracellularly and at wound sites, where it promotes cell migration into damaged tissue and participates in the inflammatory response that precedes repair. TB-500 is typically described as a synthetic analog corresponding to the actin-binding region of thymosin beta-4 — specifically the Ac-LKKTETQ sequence — the segment researchers identified as functionally relevant to the repair and migration biology. [The PubMed literature on thymosin beta-4 and TB-500](https://pubmed.ncbi.nlm.nih.gov/?term=TB-500+thymosin+beta-4) spans decades of mechanistic work: actin dynamics, corneal wound healing, cardiac repair models, tendon laceration studies in rodents. That research was almost entirely conducted with thymosin beta-4, not with the specific TB-500 fragment product. The biology is real. The question is how much of it transfers to a truncated synthetic version.

The recovery pitch

in recovery circles tb-500 is bpc-157's quieter partner — soft tissue, mobility, layered injury stacks

Athletic and recovery communities know TB-500 primarily as the secondary peptide in the BPC-157 stack. The marketing framing is complementary: BPC-157 for gut and tendon-direct effects, TB-500 for broader tissue remodeling and mobility. People reach for it after soft-tissue injuries — muscle tears, tendon strains, ligament damage — and after surgeries where return-to-training timelines feel unsatisfying. Monthly search volume runs around 19,200 queries. The claims are less dramatic than BPC-157's but no less confident online: improved flexibility, faster recovery from training, enhanced healing across tissue types. WADA classified TB-500 as a prohibited substance in governed sport, placing it alongside other peptides that regulators consider potentially performance-affecting. The prohibition is mechanism-based — regulators flag peptides tied to repair and growth biology — not based on documented doping outcomes. That is a meaningful distinction: a ban based on biological plausibility is not the same as a documented record of performance enhancement.

What the data says

a june 2026 scoping review mapped the tb4 and tb-500 literature — the human column stayed thin

A scoping review published in Applied Sciences in June 2026 attempted to give clinicians and researchers a structured map of what the thymosin beta-4 and TB-500 research record actually contains, explicitly framing its goal as distinguishing biological plausibility and preclinical signal from direct human clinical evidence. [The review is indexed in MDPI Applied Sciences](https://www.mdpi.com/2076-3417/16/12/6202). The finding mirrors what FDA staff told the PCAC in July: the foundational research on thymosin beta-4 biology is substantial and published across multiple labs — cardiac repair, wound healing, corneal models, musculoskeletal injury — and it is predominantly preclinical. Human trials of thymosin beta-4 exist in limited contexts: cardiac surgery settings, ophthalmology, a handful of small wound-healing investigations. The critical translation problem is that those studies used thymosin beta-4, not the TB-500 fragment. Whether the specific Ac-LKKTETQ sequence replicates the biological activity of the full protein is a question that has not been answered in well-designed human trials. [A search of ClinicalTrials.gov for TB-500](https://clinicaltrials.gov/search?term=TB-500) returns limited registered human study activity. The human evidence gap is exactly why the panel's yes vote came alongside FDA staff saying there was nothing to evaluate.

Anecdotal — PeptideFactCheck stance

the panel vote is regulatory policy — the anecdotal tier reflects what the evidence record shows

TB-500 holds PeptideFactCheck's Anecdotal evidence tier: claims are circulating but the science has not kept pace. The July 2026 PCAC recommendation does not change that designation. What an advisory committee vote does is open a rulemaking pathway — it does not certify that a peptide is safe or effective, and it does not mean the published evidence has caught up to what the internet says. FDA's own career scientists made the gap explicit before the vote: no human administration data, no pharmacokinetic data in people, no clinical trial results for wound healing or anything else. The panel overrode that assessment by recommending access anyway — a policy judgment about compounding availability, not a scientific finding about therapeutic benefit. Even if the rulemaking proceeds and TB-500 eventually lands on a 503A list, it would be available through licensed compounders for prescription patients with a physician-verified clinical need — not as a general recovery compound, and certainly not to validate the stack claims that drive 19,200 monthly searches. [The FDA bulk drug substances page](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) tracks where the process stands. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.